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The myelin axonal growth inhibitor NI-220/250 (Nogo-A)
has attracted considerable attention in elucidating the
mechanisms that account for the lack of plasticity in the
adult central nervous system. The cognate monoclonal
antibody IN-1, which was obtained prior to the molecular
characterization of its Nogo-A antigen, has played a crucial
role in this respect. However, this murine IgM/κ antibody
does not only provide an inappropriate format for in vivo
studies, its low antigen affinity has also hampered the
thorough structure–function analysis of its neutralizing
effect toward the Nogo-A inhibitor on a molecular basis.
We describe here the affinity maturation of a bacterially
produced functional IN-1 Fab fragment via protein engin-
eering. A soluble fragment of Nogo-A derived from the
central exon 3 of its gene, which was prepared by secretion
into the periplasm of Escherichia coli, served as a target
in these experiments. After repeated cycles of site-directed
random mutagenesis and screening, the mutant II.1.8 of
the IN-1 Fab fragment was obtained, carrying five side chain
substitutions within CDR-L3. Its dissociation constant for
the complex with the recombinant Nogo-A fragment was
determined in surface plasmon resonance measurements
as approximately 1 µM. The affinity of the unmutated
IN-1 Fab fragment was 8-fold lower. The engineered Fab
fragment appeared to be well suited for the specific detec-
tion of Nogo-A in immunochemical assays and for the
histochemical staining of myelin-rich tissue sections. Most
importantly, its concentration-dependent neutralizing effect
on the Nogo-A inhibitory activity was significantly enhanced
in cell culture. This study confirms Nogo-A to be the
antigen of the IN-1 antibody and it demonstrates increased
potential of the engineered Fab fragment as a reagent for
promoting axonal regeneration in vivo.
Keywords: affinity maturation/axonal regeneration/
bacterial expression/neuronal inhibitor/random mutagenesis
Introduction
The very limited capacity of the adult central nervous system
(CNS) for axonal regeneration is a phenomenon of broad and
ongoing scientific as well as medical interest (Ramon y Cajal,
1928; Horner and Gage, 2000). In contrast, sprouting and
elongation of lesioned axons readily occurs in the peripheral
nervous system (PNS). Inhibitory effects and non-permissible
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properties of CNS tissue, in particular of CNS myelin and
oligodendrocytes, probably contribute considerably to the
restriction of neuronal regeneration and plasticity. In vitro,
CNS myelin and oligodendrocyte membranes induce growth
cone collapse (Bandtlow et al., 1990).
Based on earlier observations of the inhibitory effect of
CNS myelin on neurite outgrowth (Caroni and Schwab, 1988a;
Spillmann et al., 1997, 1998) the myelin-associated neurite
growth inhibitor NI-220 (Spillmann et al., 1998), later called
Nogo-A (Huber and Schwab, 2000), was identified in bovine
spinal cord tissue as a predominant protein of oligodendrocytes
that prevents axonal growth. The corresponding cDNAs from
rat and man were recently described (Chen et al., 2000;
GrandPre´ et al., 2000; Prinjha et al., 2000). The nogo gene
encodes three distinct proteins, Nogo-A, Nogo-B and Nogo-C,
which apparently arise by alternative splicing and/or promoter
usage. Of those, just the full-length Nogo-A transcript is
specifically expressed in oligodendrocytes and hence is made
mainly responsible for their neuronal growth inhibitory activity
(Spillmann et al., 1998; Chen et al., 2000).
The murine monoclonal IgM/κ antibody IN-1 was originally
raised against the homologous protein NI-250 from rat CNS
myelin (Caroni and Schwab, 1988b) and cross-reacts both with
the bovine and human protein (Spillmann et al., 1997, 1998).
IN-1 was shown to effectively neutralize the inhibitory activity
in vitro (Bandtlow et al., 1990; Spillmann et al., 1998) and
in vivo, giving rise to long-distance regeneration and improved
plastic changes of injured CNS fibre tracts (Schnell and
Schwab, 1990; Z’Graggen et al., 1998). The variable domain
cDNAs of this antibody were cloned from the hybridoma cell
line, followed by the bacterial production of the corresponding
recombinant murine Fab fragment, whose functionality was
demonstrated in vitro (Bandtlow et al., 1996). A partially
humanized IN-1 Fab fragment was produced by Escherichia
coli fermentation and shown to successfully promote regenera-
tion of corticospinal axons in adult rats after spinal cord lesion
in vivo (Broesamle et al., 2000). The recombinant IN-1 Fab
fragment also induced significant elongation of injured cochlear
fibres upon intrathecal treatment (Tatagiba et al., 2002) and a
pronounced sprouting response of Purkinje cells after injection
into the intact adult cerebellum (Buffo et al., 2000).
Unfortunately, the IN-1 antibody as well as its recombinant
Fab fragment exhibit rather low antigen affinity, suggesting
that the IgM antibody was a product of the early immune
response (Bandtlow et al., 1996). Its light chain was found to
be encoded by a Vκ germline gene devoid of somatic mutations.
In the case of the IgM, the poor affinity is partially compensated
by an avidity effect due to its decavalent nature, which is
attributable to a more general mechanism in immunology, even
though at the expense of relaxed specificity in the early humoral
response. Consequently, the apparently weaker binding activity
of the monovalent Fab fragment necessitates higher concentra-
tions in order to provoke comparable in vitro activity (Bandtlow
et al., 1996).
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Nevertheless, in comparison with the intact IgM the use of
the recombinant Fab fragment is attractive for several reasons.
First, the much smaller Fab fragment was shown to possess
high stability in buffer solution and to exert efficient tissue
penetration (Bandtlow et al., 1996; Broesamle et al., 2000).
Secondly, the Fab fragment can be produced at high yields
and quickly purified to homogeneity using a well optimized
bacterial expression system (Fiedler and Skerra, 1999,
2001a,b). Finally, its recombinant format permits the applica-
tion of protein engineering techniques not only to improve its
antigen-binding activity but also to humanize the mouse-
specific immunoglobulin sequences for medical use.
Here we report the improvement of the functional affinity
of the recombinant IN-1 Fab fragment by virtue of introducing
a small set of amino acid substitutions into its antigen-binding
site. In order to perform cycles of random mutagenesis and
selection for enhanced binding activity the presumed extracel-
lular domain of the Nogo-A antigen (Chen et al., 2000; Huber
and Schwab, 2000) was produced in a bacterial expression
system, thus also permitting molecular characterization of the
cognate antigen–antibody interaction for the first time.
Materials and methods
General DNA methodology
DNA manipulations were performed according to standard
techniques (Sambrook et al., 1989). Vectors, genes and bacterial
strains were from the authors’ collection. DNA polymerases,
modifying and restriction enzymes were from generic vendors
(New England Biolabs, Frankfurt/Main, Germany; Promega,
Mannheim, Germany; Stratagene, Amsterdam, Netherlands).
Oligodeoxynucleotides for PCR and DNA sequencing were
purchased from Interactiva (Ulm, Germany). PCR reactions
were performed using a standard protocol, employing
phosphorothioate primers in conjunction with Pfu DNA poly-
merase (Skerra, 1992). Site-directed mutagenesis was carried
out with single-stranded plasmid DNA following the method of
Kunkel et al. (Kunkel et al., 1987) according to a standardized
procedure (Geisselsoder et al., 1987). All plasmid construc-
tions and mutagenesis experiments were confirmed by restric-
tion analysis, followed by DNA sequencing of relevant
regions on an ABI-Prism™ 310 Genetic Analyzer (Perkin-
Elmer/Applied Biosystems, Weiterstadt, Germany) using the
BigDye™ terminator kit.
Vector construction for Nogo fragments
A 2.3 kb Nogo-A gene fragment was amplified from the
cloned cDNA (Chen et al., 2000) via PCR with the primers
5-GCT CAG CGG CCG AGA CCC TTT TTG CTC TTC
CTp(S)G-3 (the EagI restriction site is underlined) and 5-
GCT TTT AAC TAT GCT GCC CAT TTC TGp(S)T-3. The
single PCR product was digested with EagI, purified from a
1% agarose gel, and inserted into the multiple cloning region
of pASK111 (Vogt and Skerra, 2001), which had been cut
with BsaI (resulting in a sticky end compatible with EagI) as
well as Eco47III, yielding pASK111-NiFr1. This vector leads
to the production of a mature protein with a molecular mass
of 85.0 kDa, including the Strep-tag (Skerra and Schmidt,
2000) at the C-terminus, after processing of the OmpA signal
peptide fused in-frame to the N-terminus. pASK111-NiFr2
was constructed from pASK111-NiFr1 by precisely deleting
the N-terminal 59 codons from the cloned Nogo-A gene
fragment via site-directed mutagenesis using the oligodeoxy-
nucleotide 5-GGT ATC CAT GTT CTT TAA AAG AGG
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CCT GCG CTA CGG TAG C-3. Furthermore, Cys residues
were replaced by Ser via site-directed mutagenesis with single-
stranded DNA prepared from pASK111-NiFr2 using appro-
priate oligodeoxynucleotide primers.
The C-terminal Strep-tag encoded on pASK111-NiFr2 was
exchanged for a His6 affinity tag by site-directed mutagenesis
with the oligodeoxynucleotide 5-CAC TTC ACA GGT CAA
GCT TAT TAA TGG TGA TGG TGA TGG TGA GCG CTT
TTA ACT ATG CTG CCC-3. A KasI restriction site was
concomitantly introduced at the 5-end of the cloned Nogo-A
structural gene using the oligodeoxynucleotide 5-GGT ATC
CAT GTT CTT TAA AAG AGG CGC CCT GCG CTA CGG
TAG C-3 (the KasI recognition site is underlined), resulting
in the vector pASK111-NiFr3. The region encoding the Nogo-
A fragment together with the His6-tag was finally subcloned
via KasI and NsiI (cutting within the vector, downstream of
the Camr gene) on pASK-IBA4 (Skerra and Schmidt, 2000),
which provided the coding region for an N-terminal Strep-tag
II directly downstream of the OmpA signal sequence. The
resulting vector was dubbed pASK111-NiFr4.
Vector construction for Fab fragments
The IN-1 Fab fragment and its mutants were produced utilizing
the vectors pASK88, pASK106 or pASK107. All of them
encode a chimeric Fab fragment with variable domains derived
from the mouse monoclonal antibody IN-1 (Bandtlow et al.,
1996) and human constant domains belonging to the subclass
IgG1/κ (Schiweck and Skerra, 1995). Secretion into the oxidiz-
ing milieu of the bacterial periplasm is ensured by the presence
of signal peptides at the N-termini of both chains (Skerra,
1994b) and transcription of the artificial dicistronic operon is
under tight control of the chemically inducible tetp/° (Skerra,
1994a). pASK88 (Schiweck and Skerra, 1995) was used for
soluble expression and purification via the His6-tag attached
to the C-terminus of the heavy chain (Skerra, 1994b; Fiedler and
Skerra, 2001a), whereas pASK107 (M.Fiedler and A.Skerra,
unpublished results) provided the Strep-tag II for streptavidin
affinity purification (Skerra and Schmidt, 2000) instead.
pASK106 codes for a Fab fragment similar to pASK88 but with
an albumin-binding domain (ABD) appended to the C-terminus
of the light chain (Ko¨nig and Skerra, 1998). The variable
domain genes were exchanged between the differing vector
formats using conserved restriction sites as described
(Skerra, 1994b).
Single amino acid exchanges within the IN-1 Fab fragment
or its mutants were introduced by site-directed mutagenesis.
For this purpose single-stranded DNA of the corresponding
vectors pASK88-IN1 or pASK88-I.2.6 was used in conjunction
with appropriate oligodeoxynucleotide primers. Random amino
acid substitutions were introduced into the variable domain
(VL) gene of the IN-1 light chain at defined positions via PCR
by means of degenerate oligodeoxynucleotide primers (without
the phosphorothioate modification) in conjunction with Taq
DNA polymerase. Amplification was performed on pASK85-
IN1 with the originally cloned genes (Bandtlow et al., 1996)
as template. The forward primer 5-GAC ATT GAG CTC
ACC CAG TCT CCA GCA ATC ATG KCT GC-3 (SstI
restriction site underlined) was used in all experiments whereas
the oligodeoxynucleotide 5-GCG CTT CAG CTC GAG CTT
GGT CCC AGC TCC GAA CGT MNN AGG MNN MNN
TAA CACATT TTG ACA GTA-3 (XhoI restriction site
underlined) served as backward primer for randomizing the
CDR-L3 positions L93, L94 and L96 at the first stage of
IN-1 Fab fragments with improved affinity for Nogo-A
the affinity maturation process. The second mutagenesis cycle
was performed with pASK88-I.2.6(L96V) as template and the
oligodeoxynucleotide 5-GCG CTT CAG CTC GAG CTT
GGT CCC AGC TCC GAA CGT AAC CGG CAC CCG
MNN MNN ATT TTG ACA GTA ATA CGT TGC-3 as
second primer for randomizing the positions L91 and L92
together with fixed mutations at L93, L94 and L96. In each
case, a single PCR product was obtained, purified from a 1%
agarose gel, and cut with SstI and XhoI. The resulting DNA
fragment of approximately 300 bp was ligated with the likewise
cut vector backbone of pASK106-IN1 (see above). Colonies
obtained after transformation of CaCl2-competent E.coli K-12
JM83 cells (Yanisch-Perron et al., 1985) were directly subjected
to the filter-sandwich colony-screening assay.
Bacterial protein production
Cultures of E.coli JM83 transformed with the appropriate
expression vector were grown in 2 l of Luria–Bertani (LB)
medium supplemented with the corresponding antibiotic (Amp
for derivatives of vectors pASK88, pASK106 and pASK107,
or Cam for pASK111) at 22°C and 200 r.p.m. Gene expression
was induced at an optical density (OD) of 0.5 at 550 nm by
addition of 200 µg/l anhydrotetracycline (aTc; Acros Organics,
Geel, Belgium) in the case of the Fab fragments or of 400 µg/
l aTc in the case of Nogo-A fragments. After 3 h induction the
bacteria were harvested by centrifugation and the periplasmic
protein fraction was prepared as described (Skerra and Schmidt,
2000). For the production of Nogo-A fragments 200 µg/ml
lysozyme was added to the cell fractionation buffer (50 mM
NaPi, pH 7.5, 500 mM sucrose, 1 mM EDTA).
Nogo-A fragments NI-Fr1 and NI-Fr2 were purified from
the periplasmic protein extract via the Strep-tag fused to
their C-termini employing streptavidin affinity chromato-
graphy (Skerra and Schmidt, 2000), whereby elution was
effected under mild conditions in the presence of D-desthiobi-
otin. After dialysis against a chromatography buffer (50 mM
NaPi, pH 7.5, 150 mM NaCl, 1 mM EDTA) and the concentra-
tion of the eluate (Vivaspin 15, MWCO 30 kDa; Greiner,
Frickenhausen, Germany), further purification was achieved
by gel filtration on a Superdex™ 200 prep grade column
(Pharmacia, Uppsala, Sweden) using Dynamax™ SD-300
HPLC equipment (Rainin, Woburn, MA). NI-Fr4 was first
purified by means of the His6-tag via immobilized metal
affinity chromatography (IMAC) (Skerra, 1994b) using 50
mM NaPi, pH 7.5, 1 M NaCl as the chromatography buffer
and a linear elution gradient from 0 to 75 mM imidazole·HCl
in the same buffer. The specifically eluted protein fraction was
then subjected to streptavidin affinity chromatography as above.
The recombinant IN-1 Fab fragments were purified either by
IMAC via the His6-tag fused to the C-terminus of their
heavy chain (Fiedler and Skerra, 2001a) or, when using
pASK107 (see above), via streptavidin affinity chromatography
(Schlapschy and Skerra, 2001). IMAC was also performed
under FPLC conditions using a POROS MC/M column
(0.4610 cm; PerSeptive Biosystems, Wiesbaden, Germany)
charged with Zn2 ions and Dynamax™ SD-300 HPLC
equipment (Rainin) operating at a flow rate of 2.0 ml/min. A
12.5 ml aliquot of periplasmic extract from a 2 l E.coli culture
dialysed against 50 mM NaPi, pH 7.5, 500 mM betaine was
applied to the column and, after washing with dialysis buffer,
elution was effected by application of a linear gradient of
200 mM imidazole·HCl, pH 7.5, 50 mM NaPi, 500 mM betaine
against dialysis buffer. This method enabled a 5-fold quicker
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purification compared with the conventional procedure (Fiedler
and Skerra, 2001a), yielding recombinant Fab fragments with
an apparent purity of 95% as estimated from SDS–PAGE.
The yields of purified recombinant proteins from 2 l
shaker-flask experiments were highly reproducible but varied
between 0.04 and 0.8 mg l–1 OD–1 for the different Fab
fragments and between 0.1 and 0.3 mg l–1 OD–1 for the Nogo-
A fragments. After purification the proteins were stored in
PBS (4 mM KH2PO4, 16 mM Na2HPO4, 115 mM NaCl)
containing 0.1 mM EDTA at 4°C for up to several weeks.
Protein purity was checked by SDS–PAGE using 0.1% (w/
v) SDS, 10 or 15% (w/v) polyacrylamide gels (Fling and
Gregerson, 1986) stained with Coomassie brilliant blue. The
concentration of the purified recombinant proteins was deter-
mined using calculated absorption coefficients at 280 nm (Gill
and von Hippel, 1989) of 0.41 ml mg–1 cm–1 for the Nogo-A
fragments and of 1.8 ml mg–1 cm–1 for the IN-1 Fab fragments,
respectively.
Filter-sandwich colony-screening assay
This assay was carried out based on published procedures
(Skerra et al., 1991; Schlehuber et al., 2000). Transformed
E.coli JM83 cells harbouring the pASK106 vector encoding
Fab fragments fused with the ABD (see above) were plated
on a hydrophilic membrane (GVWP, 0.22 µm; Millipore,
Bedford, MA), placed on a Petri dish with LB/Amp agar,
such that approximately 500 colonies were obtained, and
incubated at 37°C for 8–9 h. In the meantime, a hydrophobic
membrane (Immobilon™-P, 0.45 µm; Millipore) was coated
with 10 mg/ml human serum albumin (HSA; Sigma,
Deisenhofen, Germany) in PBS for 4 h and blocked with 3%
(w/v) BSA (Roth, Karlsruhe, Germany), 0.5% (v/v) Tween-20
in PBS. The membrane was washed twice with PBS, soaked
in LB/Amp containing 200 µg/ml aTc, and placed on an LB/
Amp agar plate supplemented with 200 µg/ml aTc. The first
membrane, carrying tiny colonies of the transformed cells,
was then placed onto the second (hydrophobic) membrane.
The filter sandwich was incubated for 16 h at 22°C. During
this period the mutated IN-1 Fab fragments were secreted—
and partially released from the colonies by leakage from the
bacterial periplasm—and finally immobilized on the lower
membrane via complex formation between HSA and ABD.
The first membrane with the still viable colonies was
transferred to a fresh LB/Amp agar plate and stored at
4°C. The second membrane was washed three times in PBS
containing 0.1% (v/v) Tween-20 (PBS/T) and the immobilized
Fab fragments, each in a spot corresponding to the position of
the original colony, were probed for antigen binding. To this
end recombinant Nogo-A fragment was labelled at a molar ratio
of 5:1 with digoxigenin-3-O-methylcarbonyl-ε-aminocaproic
acid N-hydroxy-succinimide ester (Roche Diagnostics,
Mannheim, Germany) and applied to the membrane for 1 h at
a concentration of 30 or 50 µg/ml in PBS/T. After washing
three times with PBS/T the membrane was incubated for 1 h
with 0.75 U/ml anti-digoxigenin Fab fragment conjugated with
alkaline phosphatase (Roche Diagnostics) in 10 ml of PBS/T.
The membrane was finally washed twice with PBS/T and
twice with PBS and the signals were developed using standard
chromogenic substrates as described (Schlehuber et al., 2000).
Colonies corresponding to signals with an intensity above
average were identified, recovered from the first membrane,
and propagated for further analysis of their recombinant gene
products.
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Enzyme-linked immunosorbent assay (ELISA)
ELISA was carried out in a 96-well microtitre plate (Becton
Dickinson, Heidelberg, Germany) at ambient temperature with
incubation steps of 1 h unless otherwise stated. Three washing
steps with PBS/T were used after each incubation, and residual
liquid was removed thoroughly. The wells were coated for 4 h
with 50 µl of a solution of NI-Fr2 at concentrations between 180
and 200 µg/ml in PBS buffer and then blocked with 200 µl
of 3% (w/v) BSA, 0.5% (v/v) Tween-20 in PBS. After washing,
50 µl of the purified recombinant Fab fragment was applied as
a dilution series in PBS/T. The wells were then incubated with
50 µl of anti-human Cκ antibody conjugated with alkaline
phosphatase (Sigma), diluted 1:1000 in PBS/T. Signals were
finally developed in the presence of p-nitrophenyl phosphate
(Voss and Skerra, 1997). Enzymatic activity was measured at
25°C as the change in absorbance at 405 nm/min with a
SpectraMAX 250 instrument (Molecular Devices, Sunnyvale,
CA). The data were corrected for background values deter-
mined in wells that were merely coated with BSA and fitted
by non-linear least squares regression as described (Voss and
Skerra, 1997).
Real-time surface plasmon resonance (SPR) measurements
Molecular interaction analysis was performed using a Biacore-
X® system equipped with the NTA-sensor chip® (Biacore
AB, Uppsala, Sweden). PBS containing 0.005% (v/v) surfactant
P20 was used as continuous flow buffer as well as for dilution
of proteins. Analysis was performed at 25°C using a flow rate
of 35 µl/min. For each measurement the derivatized chip
surface was charged with 70 µl of 0.5 mM NiSO4, followed
by immobilization of NI-Fr4 via its His6-tag in one of the two
flow channels by applying 70 µl of a 50 µg/ml solution of the
purified recombinant protein. Then, the Fab fragment (produced
by means of the vector pASK107 and purified via the Strep-
tag II) was injected at a defined concentration (between 0.25
and 6.8 µM) for 2 min, followed by buffer flow for 4 min.
The chip surface was regenerated using 70 µl of 0.35 M
EDTA, pH 8.0 in flow buffer prior to the next measurement.
Each time-dependent binding isotherm of the Fab fragment
was corrected for the background signal that was detected
in the flow channel without NI-Fr4 using BIAevaluation
software (Version 3.0). Resonance unit values for the bound
Fab fragment at equilibrium for each applied concentration
were then deduced and fitted (Voss and Skerra, 1997) by non-
linear least squares regression using an equation of the type
y  a * x / (b  x).
Immunohistochemistry
Cryosections (12 µm) of rat brain (Rattus norvegicus) were
fixed for 10 min using ice-cold ethanol. The following incuba-
tion steps were then each performed for 1 h at room temperature
in a humid chamber using PBS. Unless otherwise stated
slides were washed for 5 min with PBS. After blocking with
4% (w/v) BSA, the Fab fragment (produced using the pASK88
vector type and purified via the His6-tag) was applied at a
concentration of 100 µg/ml. After three washing steps, bound
Fab fragment was detected with an anti-human Cκ antibody
alkaline phosphatase conjugate (Sigma), diluted 1:100. The
sections were then washed three times with TBS (25 mM
Tris–HCl, pH 7.4, 145 mM NaCl, 3 mM KCl) and staining
was performed using the Fast Red kit (Roche Diagnostics).
The microscopic slides were photographed on an Axiophot




Neurite growth-modulating properties of the different Fab
fragments were tested on 4-well plastic dishes (Greiner,
Nu¨rtingen, Germany) coated with recombinant Nogo-A.
Briefly, test wells were coated for 20 min with 100 µg/ml
poly-L-lysine, washed with Hank’s balanced salt solution
(HBSS; Life Technologies, Basel, Switzerland) and coated for
2 h with 15 or 30 µg/ml of recombinant rat Nogo-A (entire
extracellular domain refolded from bacterial inclusion bodies;
T.Oertle et al., manuscript in preparation). Recombinant Nogo-
A was omitted in the wells serving for control. After aspiration,
the wells were washed with Dulbecco’s modified Eagle’s
medium (Life Technologies) containing 10% (v/v) fetal calf
serum (Life Technologies) and blocked in the same medium
for 20 min at 37°C.
Cerebellar cell cultures were prepared from rat on post-
natal day 7/8. Cells were dissociated by combined trituration
and trypsinization and purified on Percoll gradients as described
(Hatten, 1985). The cerebellar granule cells were plated in
chemically defined neurobasal medium supplemented with
B27 and 0.2 mM glutamine, 100 U/ml penicillin, and 0.1 mg/
ml streptomycin (Life Technologies). To assess the neutraliza-
tion of inhibitory acitivity, substrate-coated wells were first
incubated with 100 µg/ml of the different recombinant Fab
fragments dialysed against NaCl/Pi (137 mM NaCl, 2.7 mM
KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4, pH 7.4) for 20 min
at 37°C. The wells were then washed briefly with HBSS and
cells were applied in the presence of the Fab fragments.
Assays were stopped after 24 h in culture by adding
4% (w/v) formalin buffered with NaCl/Pi. For assaying the
inhibitory substrate properties, the proportion of total cells
bearing neurites longer than the diameter of the cell body
(indicating that neurite outgrowth was successfully initiated)
was determined. Under control conditions, i.e. in the absence
of recombinant Nogo-A, 70% of the cerebellar granule
neurons formed processes. Quantification of neurite lengths
was performed on cultures monitored with a Zeiss Axiophot
microscope. Phase contrast pictures were acquired with a 12-
bit digital CCD camera (Visicam Visitron, Germany) and
analysed using Metamorph software (Universal Imaging
Corporation, West Chester, PA). For each well, the longest
neurites of at least 100 isolated neurons were measured and
averaged. Three wells were investigated for each experimental
condition.
Results
Bacterial synthesis of a soluble Nogo-A domain
Although the precise transmembrane topology of the Nogo-A
protein has yet to be experimentally determined, its primary
structure—as deduced from the cDNA sequence (Chen et al.,
2000)—reveals several characteristic features (Figure 1). The
rat full-length protein comprises 1163 amino acids. Its
N-terminal region does not reveal a secretory signal sequence
as would be expected for a normal class I membrane protein
(von Heijne and Gavel, 1988). Instead it is highly negatively
charged. In particular, the amino acid stretch from positions
31 to 50 is almost entirely (with the exception of a single Pro)
composed of Glu and Asp residues. The acidic sequence is
followed by a region rich in Pro, Ala and—to a lesser extent—
also Ser and Gly residues, which reaches from position 61 to
171, i.e. directly up to the end of exon 1, which is followed
by a very small exon 2 (T.Oertle, et al., manuscript in
IN-1 Fab fragments with improved affinity for Nogo-A
Fig. 1. Recombinant Nogo-A fragments prepared in this study. (A) Structural characteristics of the native neurite growth inhibitor Nogo-A and of the
recombinant fragments derived from it. (B) SDS–PAGE analysis of bacterially produced NI-Fr4. Periplasmic protein extract from E.coli JM83 harbouring
pASK111-NIFr4 (lane 1); flow-through of IMAC column (lane 2); eluted protein from IMAC column as applied to the streptavidin column (lane 3); flow-
through of streptavidin column (lane 4); purified protein after streptavidin affinity chromatography (lane 5). Molecular sizes are indicated at the left.
preparation). Thus, the domain encoded by exon 1 is likely
not to adopt a regular secondary structure. In contrast, the
large Nogo-A-specific exon 3 reveals an average amino acid
composition similar to that of globular proteins. Furthermore,
it exhibits altogether eight Cys codons, whereas otherwise this
amino acid is absent in the full-length protein. This feature
might point towards the presence of disulphide bonds in the
exon 3 region as they are frequently found in extracellular
domains of membrane proteins. The C-terminal domain
encoded by exons 4–9 (for the precise exon structure refer to
T.Oertle, et al., manuscript in preparation) is short again,
comprising altogether 188 residues. It includes two stretches
of 36 (residues 990–1025) and 35 (residues 1092–1126) amino
acids, respectively, with a high content of hydrophobic side
chains, thus probably constituting transmembrane regions.
From the structural point of view the protein fragment
encoded by exon 3 is most likely folded as a globular domain
and should carry the biological active site. Consequently, we
chose the polypeptide comprising residues 174–940 (containing
767 residues, i.e. 66% of full-length Nogo-A) for production
as a recombinant protein. The gene fragment was amplified
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from the cDNA and subcloned on a standard vector for protein
production in E.coli. Using appropriate PCR primers, the
Nogo-A fragment was precisely fused at its N-terminus (i.e.
in front of residue 174) to the OmpA signal peptide, thus
effecting secretion into the bacterial periplasm, where efficient
disulphide bond formation is favoured by an oxidizing redox
environment. At the C-terminus (i.e. following residue 940)
the fragment was fused with the Strep-tag affinity peptide,
conferring binding activity towards streptavidin for simplified
purification (Skerra and Schmidt, 2000). Transcription of the
resulting hybrid gene was under tight control of the tetracycline
promoter/operator (Skerra, 1994a). The resulting protein was
denominated NI-Fr1 (Figure 1A).
Upon induction of gene expression NI-Fr1 was readily
liberated from the periplasmic protein fraction of E.coli and
purified by streptavidin affinity chromatography in one step.
SDS–PAGE analysis revealed that approximately 50% of the
recombinant protein comprised a product with the proper
length whereas 50% corresponded to a series of smaller
polypeptides, probably representing proteolytic degradation
products (data not shown). In particular, there appeared one
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prominent band just underneath that for the major recombinant
protein. Both bands were subjected to N-terminal sequencing.
The upper band yielded the sequence Glu–Thr–Leu–Phe–Ala,
which resulted from the precise cleavage of the OmpA signal
peptide. The lower band started with the amino acids Ser–
Phe–Lys–Glu–His, i.e. at a position 59 codons downstream
within the cloned sequence (beginning at residue 233 in the
full-length primary structure). Its appearance was most likely
due to the action of a bacterial protease and might indicate
that the N-terminal part of the chosen Nogo-A fragment still
belongs to a polypeptide segment devoid of well defined
structure.
In order to achieve better homogeneity of the gene product,
the first 59 residues of the mature polypeptide chain were
deleted from the cloned coding region, leading to NI-Fr2
(Figure 1A). This protein was readily produced in the periplasm
of E.coli, with similar yields as the former version but
clearly a reduced degradation pattern. The possible presence
of structural disulphide bonds in the recombinant protein was
investigated by individually substituting all eight Cys residues
(corresponding to positions 323, 403, 443, 536, 574, 676, 885
and 890 in the full-length Nogo-A sequence) with Ser via site-
directed mutagenesis. The eight mutant Nogo-A fragments
were produced in E.coli as before. However, it was not possible
to recover the mutants Cys323→Ser and Cys885→Ser from
the periplasmic protein fraction, while the mutants
Cys443→Ser and Cys890→Ser gave rise to significantly
diminished yields after Strep-tag purification when compared
with the wild-type protein. In contrast, the other four mutants
were produced at similar amounts as the original Nogo-A
fragment. These observations indicate that at least some of the
Cys residues are important for folding and may be involved
in cystine crosslinks.
The wild-type NI-Fr2 protein still gave rise to certain
truncated products, which was considered undesirable for
precise binding measurements (see below). Notably, for the
bovine bNI-220 susceptibility towards proteolysis had been
observed before (Spillmann et al., 1998). Consequently, a
doubly tagged version of the recombinant protein was prepared
using an otherwise identical expression system. First, the Strep-
tag at the C-terminus was exchanged for a His6-tag (yielding
NI-Fr3 as an intermediate construct; data not shown), and,
secondly, the Strep-tag was inserted at the N-terminus again,
downstream of the OmpA signal peptide. Interestingly, the
yield of bacterially produced soluble protein, termed NI-Fr4
(Figure 1A), was found to be significantly higher (by a factor
of 2.5, approaching 300 µg l–1 OD–1). NI-Fr4 was isolated
from the periplasmic protein fraction in two steps by IMAC
followed by streptavidin affinity chromatography. This protein
was essentially pure, just a minor fraction of truncated poly-
peptide chains was still detectable (Figure 1B).
In vitro affinity maturation of the IN-1 Fab fragment
Initial experiments on the detection of natural Nogo-A as well
as recombinant Nogo-A fragments on western blots or on
tissue sections by means of the bacterially produced IN-1 Fab
fragment revealed relatively weak signals (Bandtlow et al.,
1996), indicating that the antigen affinity was poor. From the
cloning of the variable domain genes of the IN-1 monoclonal
antibody and analysis of their sequences it was evident that
the VH domain had undergone somatic hypermutation while
the VL domain appeared to be a newly defined mouse germline
gene (Bandtlow et al., 1996). A computer modelling study
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was carried out based on a human anti-thyroid peroxidase
autoantibody (Chacko et al., 1996; PDB entry 1VGE) and a
murine anti-phenylarsonate antibody (Rose et al., 1990; PDB
entry 6FAB), both of which have sets of complementarity-
determining regions (CDRs) with the same lengths and
canonical structure determinants (Chothia et al., 1989) as IN-1
and share a high amino acid sequence similarity with it. This
analysis suggested that the CDR-L3 of IN-1 and, to a lesser
extent, its CDR-L1, were the most promising target regions
for protein engineering towards improved antigen recognition.
In particular, residue L96 and also residue L32 (in CDR-L1)
were expected to be exposed close to the centre of the
combining site and thus likely to be involved in contacts with
the antigen.
Within CDR-L1 both IN-1 and 1VGE have an Ala residue
at position L32 whereas 6FAB carries a Phe. On the other
hand, IN-1 as well as 6FAB carry an Arg at position L96 (in
CDR-L3) while 1VGE exhibits a Leu. Therefore, the structural
consequences of the amino acid exchanges AL32→F and
RL96→L within the VL domain of IN-1 were modelled, resulting
in their identification as potential paratope residues. The
corresponding single amino acid exchanges in the recombinant
Fab fragment were introduced by site-directed mutagenesis
(Fiedler and Skerra, 1999), followed by production in E.coli
and purification via IMAC (Fiedler and Skerra, 2001a). A test
for neutralizing biological activity in the 3T3 fibroblast assay
for inhibition of cell spreading on a CNS myelin substrate
(Bandtlow et al., 1996) revealed that the mutant RL96→L had
a slightly improved activity. In contrast, the mutant AL32→F
had mostly lost its neutralizing activity when compared with
the wild-type IN-1 Fab fragment (data not shown). Therefore,
the IN-1(L32F) Fab fragment was used as a negative control
during in vivo regeneration experiments of lesioned cortico-
spinal tract fibres in rats (Broesamle et al., 2000).
In order to perform functionally more complex changes
within the paratope of the IN-1 antibody a cluster of three
amino acids in CDR-L3 corresponding to positions L93, L94
and L96, was now subjected to targeted random mutagenesis.
All 20 side chains were allowed for substitution in each
position, followed by screening for improved binding of the
recombinant Nogo-A fragment via a filter-sandwich colony-
screening assay (Skerra et al., 1991; Schlehuber et al., 2000).
For this purpose, a genetic random library was prepared by
PCR amplification of the IN-1 VL gene using a degenerate
primer that carried the corresponding mixed base positions
(see Materials and methods). The mutagenized gene fragment
was recloned on the expression vector pASK106-IN1 (encoding
a Fab fragment fused with an ABD to the C-terminus of its
light chain; Ko¨nig and Skerra, 1998). E. coli JM83 was
transformed with the ligation mixture and the cell suspension
was plated on four filter membranes, placed on top of agar
plates, thus screening approximately 2000 colonies in parallel.
The antigen-binding activity of the bacterially secreted
mutants of the IN-1 Fab fragment, which became functionally
immobilized on a second membrane soaked with HSA (see
Materials and methods), was probed by incubation with
digoxigenin-labelled NI-Fr2, followed by detection with an
anti-digoxigenin Fab fragment conjugated with alkaline phos-
phatase. Colonies that gave rise to staining signals above
average were recovered, propagated, and their plasmids were
isolated for DNA sequence analysis. Out of 31 clones that were
investigated, 12 plasmids were identified carrying functional VL
genes (for the mutations see Table I). Otherwise, frameshift
IN-1 Fab fragments with improved affinity for Nogo-A
Table I. Mutants obtained from affinity maturation of the IN-1 Fab fragment
Position Signal in CSAa Expression yieldb ELISA signal
L91 L92 L93 L94 L96
IN-1 wt Val Leu Ser Thr Arg   
I.1.4 –c – Pro Val Trp   
I.1.6 – – Asn Leu Cys 
I.1.11 – – Tyr Thr Cys 
I.1.16 – – Met Cys Asn   
I.2.2 – – Arg Thr Asn   
I.2.4 – – Gly Thr Phe 
I.2.5 – – Pro Cys Val 
I.2.6 – – Arg Val Cys   
I.2.8 – – Tyr Ala Gly   –
I.2.9 – – Arg Pro Pro   –
I.3.7 – – Phe Arg Leu   –
I.4.4 – – Asp Arg Leu 
I.2.6(L96V) – – Arg Val Val  
II.1.1 Arg Lys Arg Val Val   
II.1.3 Met Lys Arg Val Val   
II.1.7 Leu Lys Arg Val Val   
II.1.8 Ile Asn Arg Val Val   
aFilter-sandwich colony-screening assay.
bIn E.coli JM83 using the vector pASK88.
cNo exchange.
mutations or internal amber termination codons were
abundant. This finding suggests a competition between
antigen-complexing signals of higher affinity mutants and
non-specific binding by conformationally defective or toxic
mutagenesis products during the colony-screening assay.
For soluble production of the recombinant Fab fragments in
a standard format (i.e. without the ABD domain but still
having a His6 tag fused to the C-terminus of the heavy chain)
the mutagenized VL gene cassettes from seven selected clones
(Table I) were subcloned on pASK88-IN1 (Fiedler and Skerra,
1999). The mutants were produced in shaker flask cultures
and isolated from the periplasmic cell fraction in one step via
IMAC. All Fab fragments contained the light and heavy chains
in stoichiometric composition and quantitatively linked via a
disulphide bond. Antigen-binding activity of the mutant Fab
fragments was subsequently tested by ELISA using the recom-
binant NI-Fr2 for coating of the microtitre plate wells (Figure
2). Almost no binding signal above background was obtained
with the recombinant wild-type IN-1 Fab fragment, illustrating
its low antigen affinity. In contrast, the mutant I.2.6 (Figure
2A) gave rise to a clearly detectable and concentration-
dependent binding signal. No significant signal was obtained
in a control experiment with BSA serving as antigen. Hence,
the mutant I.2.6 was the protein of choice for further affinity
maturation experiments.
Unfortunately, the I.2.6 mutant of the IN-1 Fab fragment
was produced as a soluble protein in E.coli at a much lower
level, with a relative yield of 5% after purification (0.04 mg
l–1 OD–1 versus 0.8 mg l–1 OD–1 for the wild-type IN-1 Fab
fragment). Obviously, the free Cys residue that occurred at
the exposed position L96 within CDR-L3 had a deleterious
influence on the folding efficiency of the Ig fragment and a
concomitant toxic effect on the bacterial host cell, as had been
similarly observed in other cases (Ostermeier et al., 1995;
Schmiedl et al., 2000). Following earlier substitution experi-
ments concerning position L96 (see above), attempts were
made to replace the Cys residue in the I.2.6 mutant by small
apolar side chains like those of Ala, Val, Met, Leu and Ile.
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The substitutions were introduced by site-directed mutagenesis
and all corresponding recombinant Fab fragments were pro-
duced and purified as before, resulting in yields that were
similar again to the wild-type IN-1 Fab fragment. However,
when binding activity towards the recombinant NI-Fr2 antigen
was tested in an ELISA, all these mutants gave rise to
significantly lower signals than the original I.2.6 Fab fragment.
Merely the replacement CysL96→Val resulted in a detectable
binding behaviour (Figure 2) and was therefore used as the
basis for the second affinity maturation cycle.
CDR-L3 forms a connecting loop between two neighbouring
β-strands such that the positions L91 and L92 are in close
spatial proximity with L96. Hence, in order to structurally
compensate a possible misfit at position L96—due to the
exchange of Cys by Val—the positions L91 and L92 within
CDR-L3 of the I.2.6(L96V) Fab fragment were subjected to
targeted random mutagenesis and the filter-sandwich colony-
screening assay was performed again. This time the stringency
of selection was raised by lowering the concentration of the
recombinant antigen (a mutant of NI-Fr2 devoid of Cys574
and Cys676) from 50 to 30 µg/ml. From screening approxi-
mately 1000 colonies spread on two filter membranes, 16
clones were identified according to their pronounced colour
signals. In contrast with the previous experiment, all of them
carried plasmids encoding functional mutants of the I.2.6(L96V)
Fab fragment. The VL gene cassettes of four clones (Table I)
were subcloned on pASK88-IN1 and the corresponding Fab
fragments were produced and purified as before. One of them,
the II.1.8 Fab fragment (Figure 2A), exhibited clearly improved
binding activity over the I.2.6(L96V) mutant in an ELISA
(Figure 2B), even though its affinity was still lower than that
of the original I.2.6 mutant carrying the free Cys residue.
Nevertheless, the yield of the II.1.8 mutant was 12-fold higher
upon expression in E.coli and thus close to that of the
recombinant wild-type IN-1 Fab fragment (0.5 versus 0.8 mg
l–1 OD–1, respectively).
Functional analysis of engineered Fab fragments
For a detailed analysis of the antigen-binding activity and
application in immunohistochemistry as well as cell culture
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Fig. 2. Structural and functional characteristics of engineered IN-1 Fab
fragments. (A) Amino acid sequence of the VL domain (Kabat database
accession no. 029919; Martin, 1996) of the monoclonal antibody IN-1
(Bandtlow et al., 1996) together with the substitutions introduced in the
course of affinity maturation. CDRs are underlined according to the
definition by Kabat et al. (Kabat et al., 1991), while amino acid positions
are numbered consecutively. The mutations obtained by exchange of
residues within CDR-L1 (Fiedler and Skerra, 1999) and CDR-L3 (this
study) are marked with bold letters below the wild-type sequence. (B)
Comparison of antigen-binding activity of engineered Fab fragments in an
ELISA. The wells of a microtitre plate were coated with recombinant NI-
Fr2 and purified Fab fragments were applied in decreasing concentration.
Bound Fab fragment was detected by means of a goat anti-human Cκ
antibody conjugated with alkaline phosphatase, followed by chromogenic
reaction.
assays, the different engineered versions of the IN-1 Fab
fragment were produced in E.coli in shaker flask cultures
and purified by IMAC to homogeneity (Figure 3A). The
thermodynamic affinity for the recombinant Nogo-A fragment
NI-Fr4 was determined both for the II.1.8 mutant and for the
wild-type IN-1 Fab fragment using the method of real-time SPR
on a Biacore-X® system. Preliminary experiments revealed
considerable difficulties in immobilizing the recombinant
Nogo-A fragments NI-Fr2 as well as NI-Fr4 to sensor chips
carrying the conventional carboxy-methylated dextran matrix
(CM5 sensor chip®) via the standard amine coupling procedure
(O’Shannessy et al., 1992). Most likely, the extremely low pI
of the Nogo-A fragment (calculated to be 4.2 for NI-Fr2 using
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Fig. 3. Antigen affinity determination for the wild-type IN-1 Fab fragment
and its mutant. (A) SDS–PAGE analysis of purified recombinant Fab
fragments prepared in this study. Fab fragments were produced in E.coli
JM83 harbouring the corresponding derivative of the vector pASK88 and
purified by IMAC. Samples in the upper part were reduced with β-
mercaptoethanol prior to gel electrophoresis whereas those in the lower part
were kept unreduced: IN-1 (wild-type) Fab fragment (lane 1); AlaL32→Phe
mutant (lane 2); I.2.6 mutant (lane 3); I.2.6(L96V) mutant (lane 4); II.1.8
mutant (lane 5). Molecular sizes are indicated at the left. All Fab fragments
appear as a homogeneous protein with stoichiometric presence of the light
and heavy chains and show quantitative formation of their interchain
disulphide bond. (B) Measurement of the concentration-dependent
interaction between the IN-1 Fab fragment and its optimized mutant II.1.8
with the recombinant Nogo-A fragment NI-Fr4 (NTA-sensor chip® charged
with 285 to 305 ∆RU) by SPR. Equilibrium values (difference in resonance
units, ∆RU) determined after subtraction of the background signal in the
absence of NI-Fr4 were plotted against the applied concentration of wild-
type IN-1 Fab fragment or its II.1.8 mutant and finally fitted by non-linear
regression.
IN-1 Fab fragments with improved affinity for Nogo-A
the GCG program package; Devereux et al., 1984) led to
electrostatic repulsion within the acceptable range of pH
conditions.
Therefore, a Ni/NTA-derivatized sensor chip (NTA-sensor
chip®; Nieba et al., 1997) was chosen, to which NI-Fr4
was immobilized via its C-terminal His6-tag (Figure 1A; see
Materials and methods). In order to prevent binding of the
recombinant Fab fragments to the same surface, their variable
domain genes were subcloned on the vector pASK107, thus
permitting purification—with comparable efficiency—via the
Strep-tag II instead of the His6-tag (see Materials and methods).
The Fab fragments were applied to the sensor chip, each time
charged with fresh antigen, at different concentrations and the
amount of bound Ig fragment was measured under equilibrium
conditions. In this way, binding isotherms were obtained for
the wild-type and engineered Fab fragments (Figure 3B), from
which dissociation constants were deduced. The KD value for
the recombinant wild-type IN-1 Fab fragment was 7.8  1.9
µM. In contrast, the dissociation constant for its II.1.8 mutant
was 1.04  0.18 µM, i.e. 8-fold better. Control experiments
with an unrelated protein, recombinant cystatin (Auerswald
et al., 1989) carrying a His6-tag (A.Skerra, unpublished results),
that was used instead of the Nogo-A fragment for coating of
the sensor chip, confirmed the absence of unspecific binding
(data not shown).
The engineered II.1.8 Fab fragment was also employed for
the detection of natural Nogo-A by immunohistochemistry.
Figure 4 shows cross-sections of adult rat brain which were
stained with different recombinant Fab fragments, followed by
a secondary antibody conjugated with a reporter enzyme.
The II.1.8 mutant specifically stained the myelinated regions,
especially the Corpus callosum and transected fibre bundles
of the Capsula interna in the Corpus striatum. The staining
pattern is similar in morphology and intensity to the one
obtained with a recombinant Fab fragment derived from the
monoclonal antibody 8-18C5, which is directed against the
major oligodendrocyte glycoprotein MOG (Linington et al.,
1984). The staining with the recombinant wild-type IN-1 Fab
fragment was very weak under the present conditions of
fixation. An unrelated recombinant anti-CD30 Fab fragment
derived from the HRS-3 antibody (Engert et al., 1990) gave
only background staining. These results demonstrate that the
affinity of the II.1.8 mutant of the IN-1 Fab fragment has been
raised to a sufficient extent in order to detect the Nogo-A
antigen in standard immunochemical experiments. Analogous
results were obtained using immunofluorescence microscopy
(data not shown).
Finally, the engineered Fab fragments were tested for their
neutralizing effect on Nogo-A substrate properties using a
cell culture assay. As shown in Figure 5, neurite outgrowth
of cerebellar granule cells was severely reduced when recom-
binant Nogo-A was used as a substrate. In contrast, in
its absence, poly-L-lysine promoted extensive attachment of
granule cells, as well as robust neurite growth with an average
neurite length of approximately 70 µm in 70% of adherent
cells. In this in vitro bioassay functional neutralization of the
inhibitory Nogo-A substrate was observed at different degrees
for the various engineered Fab fragments (Figure 5). While the
recombinant wild-type IN-1 Fab fragment revealed partial
neutralization of Nogo-A activity, as previously demonstrated
(Bandtlow et al., 1996), introduction of the mutation
AlaL32→Phe into the VL domain completely abolished this
effect. In contrast, the mutants I.2.6(L96V) and, in particular,
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Fig. 4. Specific staining of myelin-rich regions in the rat brain using the
IN-1 Fab fragment and its engineered mutants. (A) Staining was performed
with an anti-MOG Fab fragment (H.Zander et al., to be published); the
myelinated, MOG-positive Corpus callosum is marked by an asterisk and
myelinated fibres of the Capsula interna in the Corpus striatum are indicated
by arrows. (B) Staining with wild-type IN-1 Fab fragment. (C) I.2.6(L96V) Fab
fragment. (D) II.1.8 Fab fragment. (E) anti-CD30 Fab fragment (M.Schlapschy
et al., to be published). Bound Fab fragment was detected with a goat anti-
human Cκ antibody conjugated with alkaline phosphatase and revealed using
the Fast Red procedure.
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Fig. 5. Stepwise improvement of the biological activity of the IN-1 Fab
fragment during affinity maturation as determined in an in vitro neurite
outgrowth assay. The columns show the mean neurite lengths of granula
cells from the rat cerebellum cultured on a recombinant Nogo-A substrate—
or just on poly-L-lysine as a control—whose inhibitory properties were
neutralized in the presence of the IN-1 Fab fragment and its engineered
mutants (applied at 100 µg/ml). Error bars correspond to standard deviations
from triplicate experiments.
II.1.8, exhibited significantly stronger neutralizing effects, as
revealed by their better fibre growth-promoting activities, even
when the concentration of the inhibitory material was raised.
None of the applied Fab fragments exerted an effect on neurite
outgrowth of cerebellar granule cells under control conditions,
i.e. in the absence of Nogo-A. Notably, the stepwise improve-
ment of the biological activity of the mutants I.2.6(L96V) and
II.1.8 in comparison with the wild-type IN-1 Fab fragment
correlated nicely with their relative increase in antigen affinity
observed in the ELISA experiment (Figure 2B).
Discussion
In spite of its considerable potential as a reagent for studying
the biological role and distribution of the Nogo-A antigen and
for neutralizing its inhibitory effect on axonal growth in tissue
culture as well as animal experiments, the use of the monoclonal
antibody IN-1 has so far been hampered by its apparently low
antigen affinity. In the present study we were able to quantify
the intrinsic affinity of its recombinant Fab fragment to be in
the 105 M–1 range. The remarkably high dissociation constant
that was measured between the IN-1 Fab fragment and the
bacterially produced Nogo-A domain explains several observa-
tions from previous studies.
First, the antibody fragment had to be applied at a relatively
high concentration, typically 5 mg/ml (corresponding to
approximately 100 µM), in order to provoke a biological effect
(Bandtlow et al., 1996; Broesamle et al., 2000). The original
monoclonal antibody was similarly effective at a 5–10-fold
lower concentration, which is in agreement with what has to
be expected from the strong avidity effect of an IgM as soon
as it interacts with an immobilized antigen at a high surface
density. Unfortunately, the precise concentration of the IgM
was rarely used as an experimental parameter because of the
difficulties associated with its purification from the hybridoma
supernatant.
Secondly, the use of IN-1 in immunochemical detection
experiments, like western blotting, immunohistochemistry,
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fluorescence microscopy and immunoprecipitation, was
limited, and the original recombinant Fab fragment was
even dissatisfactory in this respect. In such experiments an
initial incubation period allowing for antibody–antigen
association is usually followed by several washing steps,
where the Ig protein (or the solubilized antigen) may be
quickly lost by a bleeding effect if the kinetics of dissociation
are fast. This usually happens if the thermodynamic dissociation
constant is high and it was also observed here in the course
of our Biacore measurements (data not shown). Unfortunately,
as a general implication of reaction kinetics this phenomenon
cannot be overcome by simply raising the concentration of the
applied complexing partner.
The fundamental nature of this problem explains why it
took an increased effort and repeated cycles of mutagenesis
in order to finally engineer a derivative of the IN-1 Fab
fragment with 8-fold enhanced affinity. The II.1.8 mutant
possesses a KD value equal to 1 µM, which is obviously
sufficient to yield clear antigen-binding signals in an ELISA
and to effect specific staining in immunohistochemistry on
brain sections. The preceding mutant I.2.6 might actually
perform even better, yet its exposed Cys residue at position
L96 within CDR-L3, which apparently plays a crucial role,
prevents its practical application due to poor expression in
E.coli. In this respect, one might consider switching to another
host organism. However, unpaired exposed Cys residues have
a general tendency of being post-translationally modified in
eukaryotic cells (Lyons et al., 1990) and they provide a
problem during storage because of susceptibility towards
oxidation. Nevertheless, the mutant II.1.8 IN-1 Fab fragment
with its well defined antigen-binding activity presents a promis-
ing starting point for future affinity maturation attempts, where
the mutagenesis could be focused at hypervariable regions
apart from CDR-L3, possibly even within the VH domain.
The present investigation also sheds light on aspects of the
structure and biological function of the Nogo-A antigen. First,
our data provide evidence that the epitope for the IN-1 antibody
(or its Fab fragment, respectively) resides within the protein
domain encoded by exon 3. This exon is exclusively present
in the splice form called Nogo-A, which constitutes a potent
neurite growth inhibitory protein (Chen et al., 2000; Prinjha
et al., 2000). Since the IgM as well as its recombinant Fab
fragment effectively neutralize the inhibitory effect of CNS
myelin on axonal growth (Bandtlow et al., 1996; Broesamle
et al., 2000) we conclude that the exon 3 domain is involved
in the inhibitory activity of Nogo-A. This interpretation is
in agreement with observations from immunocytochemical
staining of live oligodendrocytes with an unrelated exon 3-
specific antibody (Huber and Schwab, 2000) and with func-
tional assays based on an exon 1–3 fragment that was expressed
as an IgG Fc fusion protein (Prinjha et al., 2000). However,
an inhibitory effect on axonal regeneration was recently
reported for a region called ‘Nogo-66’, which is found between
the two hydrophobic, presumably transmembrane, segments
within the C-terminal domain of Nogo-A (GrandPre´ et al.,
2000; Fournier et al., 2001). Therefore, regardless of the
current model of its transmembrane topology, it remains
possible that both the exon 3 region and the Nogo-66 region
inhibit axon growth, possibly via differing receptors.
The fact that the exon 3 moiety of Nogo-A was readily
secreted from E.coli, including efficient processing of the
bacterial signal peptide that was attached to its N-terminus,
and recovered as a soluble protein from the periplasmic space,
IN-1 Fab fragments with improved affinity for Nogo-A
would be in agreement with the notion of its nature as an
extracellular domain. We found that several of its eight Cys
residues are important for proper folding, indicating that the
large domain may be adapted to an oxidizing extracellular
environment instead of the reducing cytosolic milieu. Even
though the native full-length Nogo-A lacks a conventional
signal peptide, which normally drives translocation of an
N-terminal extracellular domain of a transmembrane protein
across the membrane bilayer (von Heijne, 1996), peculiar post-
translational mechanisms are known which may determine
unusual topologies (Broome-Smith et al., 1994; Lu et al.,
1998). Nevertheless, it remains to be seen from future experi-
ments whether different orientations could exist for this atypical
membrane protein. The engineered IN-1 Fab fragment with
its improved affinity should provide a helpful reagent in
this respect.
The thorough characterization of the molecular interaction
between the recombinant IN-1 Fab fragment, as well as its
mutant II.1.8 with improved binding properties, and Nogo-A
constitutes an important step towards the elucidation of the
biological role of this signalling molecule. The identification
of cognate receptors on growing neurites is obviously one of
the next goals. But there is also strong interest in substances
which can neutralize the inhibitory activity of Nogo-A. Once
its active site is precisely mapped within the rather large
polypeptide chain, small cognate antagonist compounds may
be identified. However, the engineered IN-1 Fab fragment itself
provides a promising drug candidate, too. Its slower diffusion,
compared with a low molecular weight compound, together
with its moderate dissociation constant, enables site-directed
delivery on the one hand, but also prevents undesired neuronal
plasticity effects—remote from the site of application—due to
a quick dilution effect, on the other. Finally, the engineered
IN-1 Fab fragment described here offers excellent starting
conditions for the so-called humanization of its murine frame-
work sequences with the final goal of generating a potential
therapeutic agent.
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